Retatrutide and MOTS-c Research Update — May 2026

Retatrutide (also discussed as a GLP-1/GIP/glucagon triple agonist, sometimes referred to as “GLP-3” in online literature) and MOTS-c (a mitochondrial-derived peptide) continue to appear in research discussions. This post summarizes publicly available trial pipeline information and evidence quality observations as of late May 2026.

Retatrutide trial status

ClinicalTrials.gov listings for retatrutide show ongoing and completed phase 2 and phase 3 studies focused on metabolic endpoints. Researchers continue to evaluate changes in body weight, glycemic control markers, and lipid profiles. Public trial records remain the primary source for enrollment status, primary outcome measures, and estimated completion dates.

MOTS-c research context

MOTS-c is studied for its role in mitochondrial signaling and metabolic regulation in preclinical models. Human data are more limited; most publications examine mechanistic pathways rather than large-scale clinical outcomes. PubMed searches for “MOTS-c” return a mix of basic science and early translational work.

Evidence quality notes

• Retatrutide has multiple registered human trials with published protocols and some interim or final results available through trial registries and peer-reviewed channels.
• MOTS-c literature is dominated by preclinical and mechanistic studies; large, randomized human trials with hard clinical endpoints are still emerging.
• Readers should distinguish between registered trial endpoints and marketing claims that may overstate current evidence maturity.

Sources

• ClinicalTrials.gov — search “retatrutide”
• PubMed — search “MOTS-c” and “retatrutide”
• Company press releases and regulatory filings (when available)

Learn more at PeptideDailyReport.com and subscribe for weekly research briefings.